 |
Suzanne J. Baron, MD, FSCAI
Moderator
|
 |
Srihari S. Naidu, MD, FSCAI
Moderator
|
 |
Sandeep Nathan, MD, FSCAI
Speaker
|
 |
Mitul Patel, MD, FSCAI
Speaker
|
 |
Jennifer A. Rymer, MD, MBA, MHS
Speaker
|
 |
Maya Serhal, MD, FSCAI
Speaker
|
Welcoming Remarks and CME Information, Suzanne J. Baron, MD, FSCAI
Cangrelor - The Data Behind When and Why to Use IV Anti-Platelet Therapy in the Catheterization Laboratory, Jennifer A. Rymer, MD, MBA, MHS
What’s Clot Got to Do With It? Techniques for Managing Heavy Thrombus Burden, Mitul Patel, MD, FSCAI
Case Presentation of Cardiac Arrest (or Shock or STEMI), Sandeep Nathan, MD, FSCAI
Case Presentation of Complex PCI (CTO vs. MVD vs. LMCA), Maya Serhal, MD, FSCAI
Acknowledgment of Commercial Support
Upon completion of this activity, participants will be able to:
1. Review the literature supporting the use of IV P2Y12 Inhibitor therapy.
2. Utilize intravenous pharmacotherapy in treating high clot burden in the catheterization laboratory.
3. Discuss real-world cases presentations involving the use of IV P2Y12 Inhibitor therapy.
Suzanne Baron: No financial relationships with ineligible companies.
Suzanne Baron, Jennifer Rymer, and Maya Serhal: No financial relationships with ineligible companies.
Srihari S. Naidu: BMS - Advisory Board, Consulting, PI; Cytokinetics - Advisory Board, Consulting, PI; Zoll Therox - Advisory Board, Consulting, PI; Tenaya - Advisory Board.
Sandeep Nathan: Getinge - Consulting; Medtronic - Consulting; Merit Medical - Consulting; Terumo - Consulting; Zoll - Consulting.
Mitul Patel: Bolt Medical - Stocks, Consulting; Boston Scientific Corp. - Consulting; Medtronic - Consulting.
Binita Shah: No financial relationships with ineligible companies.
Laura Porter: No financial relationships with ineligible companies